{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:49:33Z","timestamp":1791521373680,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.farma.2026.04.018","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:03:17Z","timestamp":1791518597000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["[Translated article] The \u201cTrojan horse\u201d against antimicrobial resistance: Siderophore conjugates and public health"],"prefix":"10.1016","author":[{"given":"Alina Dammar","family":"Herrera-Callo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Roberto","family":"Ch\u00e1vez-Mor\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10325","key":"10.1016\/j.farma.2026.04.018_bb0005","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.farma.2026.04.018_bb0010","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/phar.1868","article-title":"Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications","volume":"37","author":"Luepke","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.farma.2026.04.018_bb0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41579-019-0288-0","article-title":"The global preclinical antibacterial pipeline","volume":"18","author":"Theuretzbacher","year":"2020","journal-title":"Nat Rev Microbiol"},{"issue":"9","key":"10.1016\/j.farma.2026.04.018_bb0020","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","article-title":"Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases","volume":"13","author":"Munoz-Price","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.farma.2026.04.018_bb0025","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1093\/jac\/dkv086","article-title":"Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study","volume":"70","author":"Tumbarello","year":"2015","journal-title":"J Antimicrobial Chemother"},{"issue":"4","key":"10.1016\/j.farma.2026.04.018_bb0030","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"van Duin","year":"2017","journal-title":"Virulence"},{"issue":"10325","key":"10.1016\/j.farma.2026.04.018_bb0035","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"GBD","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.farma.2026.04.018_bb0040","unstructured":"O'Neill J. Tackling drug-resistant infections globally: final report and recommendations the review on antimicrobial resistance chaired by Jim O'Neill. Published online 2016. [accessed 19 May 2026]. Available from: https:\/\/amr-review.org\/sites\/default\/files\/160525_Final%20paper_with%20cover.pdf."},{"issue":"11","key":"10.1016\/j.farma.2026.04.018_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3201\/eid2811.220415","article-title":"Increased detection of carbapenemase-producing enterobacterales bacteria in Latin America and the Caribbean during the COVID-19 pandemic","volume":"28","author":"Thomas","year":"2022","journal-title":"Emerg Infect Dis"},{"issue":"Supplement_7","key":"10.1016\/j.farma.2026.04.018_bb0050","doi-asserted-by":"crossref","first-page":"S544","DOI":"10.1093\/cid\/ciz827","article-title":"In vitro activity of cefiderocol against a broad range of clinically important Gram-negative bacteria","volume":"69","author":"Yamano","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"18","key":"10.1016\/j.farma.2026.04.018_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24183314","article-title":"Siderophore\u2013antibiotic conjugate design: new drugs for bad bugs?","volume":"24","author":"Negash","year":"2019","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.farma.2026.04.018_bb0060","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.farma.2026.04.018_bb0065","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1039\/D2MD00465H","article-title":"Siderophore conjugates to combat antibiotic-resistant bacteria","volume":"14","author":"Rayner","year":"2023","journal-title":"RSC Med Chem"},{"issue":"8","key":"10.1016\/j.farma.2026.04.018_bb0070","doi-asserted-by":"crossref","first-page":"9149","DOI":"10.3390\/cimb46080541","article-title":"Antimicrobial activity of Gallium(III) compounds: pathogen-dependent targeting of multiple iron\/heme-dependent biological processes","volume":"46","author":"Choi","year":"2024","journal-title":"Curr Issues Mol Biol"},{"issue":"5","key":"10.1016\/j.farma.2026.04.018_bb0075","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jinf.2018.02.007","article-title":"Mortality due to KPC carbapenemase-producing Klebsiella pneumoniae infections: systematic review and meta-analysis: mortality due to KPC Klebsiella pneumoniae infections","volume":"76","author":"Ramos-Casta\u00f1eda","year":"2018","journal-title":"J Infect"},{"issue":"7","key":"10.1016\/j.farma.2026.04.018_bb0080","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.3390\/microorganisms13071697","article-title":"Global epidemiology and antimicrobial resistance of Klebsiella pneumoniae carbapenemase (KPC)-producing Gram-negative clinical isolates: a review","volume":"13","author":"Falagas","year":"2025","journal-title":"Microorganisms"},{"key":"10.1016\/j.farma.2026.04.018_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105627","article-title":"Global emergence of carbapenem-resistant hypervirulent Klebsiella pneumoniae driven by an IncFIIK34 KPC-2 plasmid","volume":"113","author":"Jiang","year":"2025","journal-title":"EBioMedicine"},{"issue":"10474","key":"10.1016\/j.farma.2026.04.018_bb0090","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","article-title":"Multidrug-resistantGram-negative bacterial infections","volume":"405","author":"Macesic","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.farma.2026.04.018_bb0095","unstructured":"ECDC. Assessing the health burden of infections with antibiotic-resistant bacteria in the EU\/EEA, 2016\u20132020. Published online 2022. [accessed 19 May 2026]. Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/health-burden-infections-antibiotic-resistant-bacteria-2016-2020"},{"key":"10.1016\/j.farma.2026.04.018_bb0100","series-title":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","author":"WHO","year":"2017"},{"issue":"8","key":"10.1016\/j.farma.2026.04.018_bb0105","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/antibiotics9080514","article-title":"Clinical and economic burden of carbapenem-resistant infection or colonization caused by Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii: a multicenter study in China","volume":"9","author":"Zhen","year":"2020","journal-title":"Antibiotics (Basel)"},{"issue":"suppl_2","key":"10.1016\/j.farma.2026.04.018_bb0110","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1093\/cid\/ciy642","article-title":"In-hospital medical costs of infections caused by carbapenem-resistant Klebsiella pneumoniae","volume":"67","author":"Huang","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.farma.2026.04.018_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-022-07548-3","article-title":"Economic and clinical burden from carbapenem-resistant bacterial infections and factors contributing: a retrospective study using electronic medical records in Japan","volume":"22","author":"Imai","year":"2022","journal-title":"BMC Infect Dis"},{"issue":"11","key":"10.1016\/j.farma.2026.04.018_bb0120","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41579-022-00745-6","article-title":"Nutritional immunity: the battle for nutrient metals at the host\u2013pathogen interface","volume":"20","author":"Murdoch","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.farma.2026.04.018_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1465719","article-title":"Non-classical roles of bacterial siderophores in pathogenesis","volume":"14","author":"Arnold","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"10.1016\/j.farma.2026.04.018_bb0130","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/1751-7915.14241","article-title":"Mechanisms of iron homeostasis in Pseudomonas aeruginosa and emerging therapeutics directed to disrupt this vital process","volume":"16","author":"S\u00e1nchez-Jim\u00e9nez","year":"2023","journal-title":"J Microbial Biotechnol"},{"issue":"1","key":"10.1016\/j.farma.2026.04.018_bb0135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev-micro-032421-111116","article-title":"TonB-dependent transport across the bacterial outer membrane","volume":"77","author":"Silale","year":"2023","journal-title":"Annu Rev Microbiol"},{"issue":"6","key":"10.1016\/j.farma.2026.04.018_bb0140","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/antibiotics11060706","article-title":"Are virulence and antibiotic resistance genes linked? A comprehensive analysis of bacterial chromosomes and plasmids","volume":"11","author":"Darmancier","year":"2022","journal-title":"Antibiotics Basel"},{"issue":"1","key":"10.1016\/j.farma.2026.04.018_bb0145","doi-asserted-by":"crossref","first-page":"7791","DOI":"10.1038\/s41598-022-11984-1","article-title":"Molecular epidemiology and collaboration of siderophore-based iron acquisition with surface adhesion in hypervirulent Pseudomonas aeruginosa isolates from wound infections","volume":"12","author":"Tahmasebi","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.farma.2026.04.018_bb0150","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s44259-024-00053-4","article-title":"Siderophores as tools and treatments","volume":"2","author":"Gr\u00e4ff","year":"2024","journal-title":"npj Antimicrob Resist"},{"issue":"1","key":"10.1016\/j.farma.2026.04.018_bb0155","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acs.jmedchem.2c01489","article-title":"Trojan horse siderophore conjugates induce Pseudomonas aeruginosa suicide and qualify the TonB protein as a novel antibiotic target","volume":"66","author":"Peukert","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.farma.2026.04.018_bb0160","series-title":"Gemini 3 Flash [artificial intelligence model]","author":"Google","year":"2026"},{"issue":"1","key":"10.1016\/j.farma.2026.04.018_bb0165","doi-asserted-by":"crossref","DOI":"10.1128\/ecosalplus.esp-0015-2022","article-title":"Siderophore cephalosporins","volume":"13","author":"Page","year":"2025","journal-title":"EcoSal Plus"},{"key":"10.1016\/j.farma.2026.04.018_bb0170","article-title":"Cefiderocol for the treatment of multidrug-resistant Gram-negative bacteria: a systematic review of currently available evidence","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.farma.2026.04.018_bb0175","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.farma.2026.04.018_bb0265","series-title":"IDWeek 2023: shionogi presents new real-world evidence demonstrating effectiveness of earlier","author":"Shionogi & Co. Ltd","year":"2023"},{"key":"10.1016\/j.farma.2026.04.018_bb0270","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05821-1","article-title":"Total synthesis and antimicrobial evaluation of natural albomycins against clinical pathogens","volume":"9","author":"Lin","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.farma.2026.04.018_bb0275","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1021\/acsinfecdis.2c00523","article-title":"Synthesis and characterization of DOTAM-based sideromycins for bacterial imaging and antimicrobial therapy","volume":"9","author":"Peukert","year":"2023","journal-title":"ACS Infect Dis"},{"issue":"11","key":"10.1016\/j.farma.2026.04.018_bb0280","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1021\/acsinfecdis.1c00458","article-title":"Conjugation of aztreonam, a synthetic monocyclic \u03b2-lactam antibiotic, to a siderophore mimetic significantly expands activity against Gram-negative bacteria","volume":"7","author":"Liu","year":"2021","journal-title":"ACS Infect Dis"},{"issue":"1","key":"10.1016\/j.farma.2026.04.018_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41181-024-00249-z","article-title":"Preclinical characterisation of Gallium-68 labeled ferrichrome siderophore stereoisomers for PET imaging applications","volume":"9","author":"Krasulova","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"6","key":"10.1016\/j.farma.2026.04.018_bb0180","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02371-23","article-title":"Heteroresistance to cefiderocol in carbapenem-resistant acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysis","volume":"11","author":"Longshaw","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"1","key":"10.1016\/j.farma.2026.04.018_bb0185","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13613-023-01146-5","article-title":"Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence","volume":"13","author":"Viale","year":"2023","journal-title":"Ann Intensive Care"},{"issue":"3","key":"10.1016\/j.farma.2026.04.018_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.100992","article-title":"Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses","volume":"6","author":"Melchiorri","year":"2025","journal-title":"Lancet Microbe"},{"issue":"1","key":"10.1016\/j.farma.2026.04.018_bb0195","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s41181-024-00249-z","article-title":"Preclinical characterisation of gallium-68 labeled ferrichrome siderophore stereoisomers for PET imaging applications","volume":"9","author":"Krasulova","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"6","key":"10.1016\/j.farma.2026.04.018_bb0200","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3390\/pharmaceutics13060773","article-title":"Challenge in the discovery of new drugs: antimicrobial peptides against WHO-list of critical and high-priority bacteria","volume":"13","author":"Roque-borda","year":"2021","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.farma.2026.04.018_bb0205","first-page":"681","article-title":"P\u00e9ptidos antimicrobianos, una alternativa prometedora para el tratamiento de enfermedades infecciosas","volume":"154","author":"Olascoaga-Del Angel","year":"2018","journal-title":"Gac Med Mex"},{"key":"10.1016\/j.farma.2026.04.018_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fddsv.2024.1440378","article-title":"Metal-antimicrobial peptides combo: promising weapons to combat bacteria invaders","volume":"4","author":"Falcigno","year":"2024","journal-title":"Front Drug Discov"},{"key":"10.1016\/j.farma.2026.04.018_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114640","article-title":"Pharmaceutical nanotechnology: antimicrobial peptides as potential new drugs against WHO list of critical, high, and medium priority bacteria","volume":"241","author":"Roque-Borda","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.farma.2026.04.018_bb0220","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202410893","article-title":"Antimicrobial peptides: a promising alternative to conventional antimicrobials for combating polymicrobial biofilms","volume":"12","author":"Roque-Borda","year":"2025","journal-title":"Adv Sci"},{"issue":"16","key":"10.1016\/j.farma.2026.04.018_bb0225","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.3390\/molecules29163889","article-title":"Location, location, location: establishing design principles for new antibacterials from ferric siderophore transport systems","volume":"29","author":"Luo","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.farma.2026.04.018_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114921","article-title":"Synthesis and study of new siderophore analog-ciprofloxacin conjugates with antibiotic activities against Pseudomonas aeruginosa and Burkholderia spp.","volume":"245","author":"Loupias","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"6","key":"10.1016\/j.farma.2026.04.018_bb0235","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3390\/biom13060959","article-title":"Engineering siderophore biosynthesis and regulation pathways to increase diversity and availability","volume":"13","author":"Puja","year":"2023","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.farma.2026.04.018_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s44259-025-00123-1","article-title":"Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria","volume":"3","author":"Gargate","year":"2025","journal-title":"npj Antimicrobials Resist"},{"issue":"9","key":"10.1016\/j.farma.2026.04.018_bb0245","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1038\/s41591-024-03218-w","article-title":"Advancing global antibiotic research, development and access","volume":"30","author":"Piddock","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.farma.2026.04.018_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2023.100705","article-title":"Challenges and opportunities for incentivising antibiotic research and development in Europe","volume":"33","author":"Anderson","year":"2023","journal-title":"Lancet Regional Health \u2013 Europe"},{"key":"10.1016\/j.farma.2026.04.018_bb0255","series-title":"Un informe destaca los avances en los esfuerzos para incentivar la investigaci\u00f3n y el desarrollo de antibi\u00f3ticos","author":"CIDRAP","year":"2024"},{"issue":"10","key":"10.1016\/j.farma.2026.04.018_bb0260","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1093\/cid\/ciab887","article-title":"A nonprofit drug development model is part of the antimicrobial resistance (AMR) solution","volume":"74","author":"Piddock","year":"2022","journal-title":"Clin Infect Dis"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001741?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001741?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:03:30Z","timestamp":1791518610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326001741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":57,"alternative-id":["S1130634326001741"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.04.018","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] The \u201cTrojan horse\u201d against antimicrobial resistance: Siderophore conjugates and public health","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.04.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}